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Abstract Topoisomerase IIb binding protein 1 (TopBP1)
is involved in cell survival, DNA replication, DNA damage
repair and cell cycle checkpoint control. The biological
function of TopBP1 and its close relation with BRCA1
prompted us to investigate whether alterations in the
TopBP1 gene can influence the risk of breast cancer.
The aim of this study was to examine the association
between five polymorphisms (rs185903567, rs116645643,
rs115160714, rs116195487, and rs112843513) located in
the 30UTR region of the TopBP1 gene and breast cancer
risk as well as allele-specific gene expression. Five hundred
thirty-four breast cancer patients and 556 population con-
trols were genotyped for these SNPs. Allele-specific Top-
BP1 mRNA and protein expressions were determined by
using real time PCR and western blotting methods,
respectively. Only one SNP (rs115160714) showed an
association with breast cancer. Compared to homozygous
common allele carriers, heterozygous and homozygous for
the T variant had significantly increased risk of breast
cancer (adjusted odds ratio = 3.81, 95 % confidence
interval: 1.63–8.34, p = 0.001). Mean TopBP1 mRNA and
protein expression were higher in the individuals with the
CT or TT genotype. There was a significant association
between the rs115160714 and tumor grade and stage. Most
carriers of minor allele had a high grade (G3) tumors
classified as T2-T4N1M0. Our study raises a possibility
that a genetic variation of TopBP1 may be implicated in
the etiology of breast cancer.
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Introduction
Breast cancer is the most frequently diagnosed cancer and
one of the leading causes of cancer death among women
worldwide [1]. In Poland breast cancer is the second most
common cause of cancer death in women. Moreover, breast
cancer incidence rates have been reported to increase by up
to 5 % per year in developing countries [2]. Although
environmental factors and lifestyle could contribute to the
increased breast cancer risk, genetic factors are also
implicated in the pathogenesis of the disease. Recent
genome-wide and candidate gene association studies have
identified some low-penetrance variants associated with
breast cancer [3, 4]. However, despite great progress in the
breast cancer studies the molecular mechanisms that con-
tribute to breast carcinogenesis remain poorly understood.
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Thus, there is a necessity to identify all breast cancer
susceptibility genes.
TopBP1 protein was first identified as an interacting
partner for topoisomerase IIb. TopBP1 gene comprising 28
exons is located on chromosome 3q22.1 and encodes a 1,522
amino acid protein (180 kDa) [5]. TopBP1 protein seems to
be essential for maintenance of chromosomal integrity and
cell proliferation. This protein appears to be involved in
DNA replication, DNA damage response and cell cycle
checkpoint control [6, 7]. The most striking feature of
TopBP1 is that it has eight BRCA1 C-terminal (BRCT)
domains which were first identified in breast cancer gene 1
(BRCA1) [8, 9]. BRCT domains, about 90 amino acids in
length are hydrophobic and are involved in interaction with
other proteins as well as in interaction with single and
double-stranded DNA [10]. The C-terminal region of Top-
BP1 containing two BRCTs is responsible for interaction
with topoisomerase and shows considerable similarities with
BRCA1. Apart from structural similarities TopBP1 shares
many other common features with BRCA1. Both TopBP1
and BRCA1 are strongly induced during S phase. Following
ionizing radiation, TopBP1 is recruited to DNA breaks and
colocalizes with Nbs1 (Nijmegen breakage syndrome 1),
BRCA1 and 53BP1 (p53-binding protein 1) in nuclear foci.
TopBP1 and BRCA1 also colocalize with proliferating cell
nuclear antigen at stalled replication forks after a replication
block. Both proteins are phosphorylated by ATM (ataxia
telangiectasia mutated) kinase in response to DNA damage
and DNA replication stress [5]. Moreover, it was shown that
TopBP1 is involved in regulation of p53 activities during
normal growth.
The biological function of TopBP1 and its close relation
with BRCA1 prompted us to investigate whether genetic
alterations in the TopBP1 gene can influence the risk of
breast cancer. In present study we tested the effect of SNPs
potentially located in the 30UTR (30untranslated region)
region of the TopBP1 gene and listed in NCBI’s (National
Center for Biotechnology Information) SNP database on
breast cancer risk as well as on allele-specific mRNA/protein
expression. There are five such SNPs—rs185903567 (G/A),
rs116645643 (A/G), rs115160714 (C/T), rs116195487 (C/G),
and rs112843513 (C/delC)]. We correlated obtained results
with clinicopathological characteristics.
Materials and methods
Study population
This study involved 534 women with non-hereditary
infiltrating ductal breast carcinomas (age range 43–81,
mean age 54.76 ± 7.35) recruited between May 2003 and
November 2010. The patients had a confirmed diagnosis of
ductal breast cancer based on histopathological evaluation
and were under treatment at the Polish Mothers Memorial
Hospital Research Institute, Ło´dz´, Poland. None of the
recruited patients received preoperative chemo- or radio-
therapy. Patients diagnosed with previous breast tumors or
with tumors located elsewhere were excluded.
A group of 556 healthy Polish individuals were col-
lected from the hospital routine controls of health and used
as control. They were non-related women, that have never
been diagnosed with breast tumors, other tumors or chronic
disease and were randomly selected and frequency mat-
ched to the cases on age (age range 34–83, mean age
51.27 ± 11.18).
Blood samples were collected from all women partici-
pating in the study and additionally breast cancer tissues
were obtained from patients with breast neoplasms. We
enrolled only women born and living in central Poland
(Ło´dz´ region). Informed consent was obtained from
patients and controls, and ethics approval was obtained
from the ethics commission of the Polish Mother’s
Memorial Hospital, Research Institute (G4/2011).
Lifestyle risk factors
Study participants were interviewed using questionnaire
that included socio-demographic, medical history, health
related information, alcohol intake, smoking status, men-
strual and reproductive histories, and exogenous hormone
use. Medical records of patients were thoroughly reviewed.
The tumor stages were classified according to the 1997
TNM staging system of the American Joint Committee on
Cancer [11]. Tumors were graded according to the Bloom
and Richardson classification, modified by Elston and Ellis
[12]. A positive family history of breast cancer was defined
as reporting of breast cancer in one or more first degree
relatives. Body mass index (BMI) was calculated based on
current weight in kilograms divided by height in meters
squared.
The subjects were classified as never/rare drinkers, ex-
drinkers, or current drinkers who consumed 1–8.9 U/week
(light drinkers), 9–17.9 U/week (moderate drinkers), or
18 U/week (heavy drinkers), where 1 U = 22 g ethanol
[13].
According to smoking status patients and controls were
grouped into ‘‘never’’, ‘‘former’’ and ‘‘current’’ based on
self-reported usage. Participants who reported smoking at
least 100 cigarettes in their lifetime and who, at the time of
survey, smoked either every day or some days were defined
as Current Smoker. Participants who reported smoking at
least 100 cigarettes in their lifetime and who, at the time of
the survey, did not smoke at all were defined as Former
Smoker. Participants who reported never having smoked
100 cigarettes were defined as Never Smoker.
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Menopause was defined as the time of the last menstrual
period (or menstrual flow of any amount). None of the
women involved in the study had undergone a hysterec-
tomy. Regular drug usage was defined as self-report use of
oral contraceptives or menopausal hormones for 6 months
or longer.
Blood sample collection, SNP selection and genotyping
Each genomic DNA sample was extracted from peripheral
blood using FlexiGene DNA Kit (Qiagen GmbH, Hilden,
Germany). DNA concentration was determined by spectro-
photometry. The single nucleotide polymorphisms (SNPs)
rs185903567 (G/A), rs116645643 (A/G), rs115160714
(C/T), rs116195487 (C/G), rs112843513 (C/delC) located at
the 30UTR of TopBP1 gene and listed in the NCBI’s SNP
database were evaluated. These polymorphisms were ana-
lyzed by PCR amplification and direct sequencing. The
amplified region included the entire 30UTR region (nucleo-
tides 4629-5289; NCBI Reference Sequence: NM_007027.3).
Briefly, amplification was carried out in a final volume of
25 ll containing 100 ng genomic DNA, 0.3 lM of forward
(50-TGGGACTGGATTATCACAAAAG-30) and reverse (50-
CTTTTATTCTTTATTGTCACATTTTCC-30) primers, 0.2
mM dNTPs (deoxyribonucleoside triphosphates), 2 mM
MgCl2, 1 9 Buffer (Applied Biosystems, Darmstadt, Ger-
many) and 1 U AmpliTaq Gold (Applied Biosystems,
Darmstadt, Germany). PCR conditions were 94 C for 5 min;
35 cycles with denaturation at 94 C for 30 s, annealing at
61 C for 30 s, and elongation at 72 C for 30 s; and a final
extension at 72 C for 10 min. Purified PCR products were
then sequenced using BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Darmstadt, Germany)
and electrophoresed on a 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA).
Total RNA extraction and cDNA synthesis
Total RNA was extracted from breast cancer tissues using
TRI Reagent (Sigma Aldrich Corp. St. Louis, MO, USA)
according to manufacturer’s protocol. RNA was eluted in
20 ll RNase-free water, quantified by spectrophotometry
at 260 nm and stored at -20 C. RNA with a 260/280 nm
ratio in range 1.8–2.0 was considered high quality. First-
strand cDNAs were obtained by reverse transcription of
1 lg of total RNA using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas UAB, Vilnius, Lithuania) fol-
lowing the manufacturer’s protocol.
Real time quantitative PCR
For real-time PCR analysis of TopBP1 mRNA in normal and
pathological tissues, TaqMan Gene Expression Assays
(Applied Biosystems, Bedford, MA, USA) were used
according to the manufacturer’s instruction. Before starting
the real-time PCR analysis we used the NormFinder algo-
rithm to select the best reference gene (http://www.mdl.dk).
We chose GAPDH (glyceraldehyde 3-phosphate dehydroge-
nase) gene because it had the lowest stability value-0.017.
The fluorogenic, FAM labeled probes and the sequence spe-
cific primers for TopBP1 and GAPDH were obtained as
inventoried assays Hs00199775_m1 and Hs99999905_m1,
respectively (Applied Biosystems, Bedford, MA, USA). The
reactions were performed in duplicate. A positive result was
defined by a threshold cycle (Ct) value lower than 40 (the Ct
value is determined by the number of cycles needed to exceed
the background signal). Ct value of all positive results were
lower than 30. Abundance of TopBP1 mRNA in studied
material was quantified by the DCt method. DCt (CtTopBP1
- CtGAPDH) values were recalculated into relative copy
number values (number of copies of TopBP1 mRNA per
1,000 copies of GAPDH mRNA).
Western blotting analysis
Tissue homogenate was obtained from each sample in the
presence of the serine protease inhibitor PMSF (phenyl-
methylsulfonyl fluoride) and 10 mM sodium molybdate.
The protein content was estimated by modified Lowry
method using bovine serum albumin as standard. Homog-
enate proteins (50 lg protein/lane) were resolved by 8 %
SDS-PAGE and electroblotted onto Immobilon-P transfer
membranes (Millipore, Bedford, MA, USA). The blots
were incubated 1 h with rabbit polyclonal anti-TopBP1
(Abcam, Cambridge, UK) in a 1:1,000 dilution. After being
washed three times with TBST (Tris buffered saline with
Tween-20), the membranes were incubated 1 h with goat
anti-rabbit antibodies conjugated with horseradish peroxi-
dase (1:5,000 dilution). The membranes were again washed
three times with TBST and incubated with peroxidase
substrate solution (3,30-diaminobenzidine—DAB). Gel-
Pro Analyzer software (Media Cybernetics Inc.,
Bethesda, MD, USA) was used for densitometry analysis of
protein bands. The integrated optical density (IOD) of the
bands, in a digitized picture, was measured.
Evaluation of estrogen receptor and progesterone
receptor
Estrogen receptor (ER) and progesterone receptor (PR)
status was determined by immunohistochemical method as
part of the routine clinical practice. Using the immuno-
histochemical assay, tumors were classified as positive if
more than 10 % of the cells showed nuclear staining for the
receptor. This information was received together with the
characteristics of clinical material.
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Quality control
For quality control purposes, 10 % of samples were ran-
domly selected, and sequence analysis performed, with
100 % concordance to the genotype. Laboratory personnel
were unable to distinguish among case, control, and quality
control samples.
Statistical data analysis
Genotype distributions were evaluated for agreement with
Hardy–Weinberg equilibrium by the Chi-square test.
Unconditional multiple logistic regression models were
used to calculate odds ratios (ORs) and 95 % confidence
intervals (CIs) for the association of genotype with breast
cancer risk. Genotype data were analyzed with the homo-
zygote of the common allele as the reference group.
Variants of homozygotes and heterozygotes were com-
bined to evaluate the dominant effect. For each SNP, trend
tests were conducted by assigning the ordinal values 1, 2,
and 3 to homozygous wild-type, heterozygous, and
homozygous variant genotypes, respectively, and by add-
ing these scores as a continuous variable in logistic
regression model. All multivariate models were adjusted
for age, family history, obesity, smoking status, parity,
menopausal status, and use of contraceptive and meno-
pausal hormones. Since levels of TopBP1 mRNA and
protein expression in studied material specimens did not
show normal distribution (Kolmogorov–Smirnov test) the
non-parametrical statistical tests (Mann–Whitney U test,
Kruskal–Wallis test with post hoc multiple comparisons,
Chi square test or the Spearman rank correlation test) were
applied. Reported p values were two-sided. Probabilities
were considered significant whenever p-value was lower
than 0.05. All analyses were completed using SAS software
(version 9.0 SAS Institute, Cary, NC, USA).
Results
Characteristics of subjects
The distributions of sociodemographic characteristics,
lifestyle risk factors and clinical characteristics of the
patients are shown in Tables 1 and 2, respectively. All
patients and healthy subjects were Caucasian. The cases
were slightly older (mean age 54.76 ± 7.35 vs. 51.27 ±
11.18), were more likely to have an BMI equal or greater
than 30 (39.9 vs. 28.9 %) and more likely to use contra-
ceptives (estrogens and progestins) and menopausal hor-
mones 64.4 vs. 50.1 % and 42.3 vs. 30.9 %, respectively,
than controls. Moreover, both groups slightly differ in
smoking status. More patients currently smoke (37.1 vs.
26.2 %) and fewer had never smoked (18.0 vs. 27.9 %,)
than women in control group.
Genotypes and genotypic distribution in patients
and control subjects
Genotype distributions for TopBP1 polymorphisms in 534
breast cancer patients and 556 control subjects are sum-
marized in Table 3. Two SNPs (rs116195487 and
rs185903567) were not observed in the 30UTR region of
TopBP1 gene in our studied groups. During the study, we
have not identified any new mutations, not listed in the
SNP databases. All cases and controls were common allele
carriers. Only one SNP (rs115160714) showed an associ-
ation with breast cancer. The frequency of individuals who
carried (T) allele was significantly higher in cases group
(3.1 %) than in controls group (0.8 %; p \ 0.001). Com-
pared to homozygous common allele carriers, heterozygous
for the T variant were found to be at a significant 3.54-fold
increased risk of breast cancer (95 % CI = 1.56–8.39;
p = 0.002). The TT genotype even more increased breast
cancer risk compared with those harboring the CC geno-
types (OR = 5.40, 95 % CI = 0.63–46.64; p = 0.004).
The comparison of combined genotypes is shown in
Table 4. Most cases and controls showed only one SNP
polymorphism. However, nineteen cases (3.5 %) were
heterozygotes for rs115160714 and had a C deletion in
rs112843513.
Association of rs115160714 with clinical
and environmental parameters
Of the 534 breast cancer patients, 406 (76.0 %) had a low
grade tumor (grades G1 and G2), and 128 (24.0 %) had a
high grade tumor (G3). Most tumors, 389 (72.8 %) was
classified as T1-2N0M0, and the remaining 145 (27.2 %)
was T2-4N1M0 (Table 5). There was a significant associ-
ation between CT and TT genotypes and tumor grade or
stage. Most carriers of minor allele had a high grade tumors
classified as T2-4N1M0 (Table 5).
The analysis of SNP polymorphism (rs115160714) in
smokers and non-smokers groups showed that smoking is a
significant breast cancer risk factor in case of T allele
carriers (Table 6). There was no association between
alcohol intake and breast cancer risk.
Association between TopBP1 genotypes and mRNA/
protein expression in breast cancer tissue
We found that mean TopBP1 mRNA expression was lower
in the case of individuals with the CC genotype than in case
of minor allele carriers, i.e. CT heterozygotes and TT
3496 Mol Biol Rep (2013) 40:3493–3502
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homozygotes (223.0, 412.0 and 428.5 copies of TopBP1
mRNA per 1000 copies of GAPDH mRNA, respectively,
p \ 0.05 for all comparisons) (Table 7; Fig. 1a). We found
TopBP1 protein expression in 81.2, 69.5 and 60.0 % of
breast tissue homogenate samples of CC, CT, and TT
genotype carriers, respectively. Although the protein
expression was more frequently observed in common allele
carriers group, the mean expression level was lower than in
minor allele carriers (84.6, 118.2, 127.4 IOD relative units,
respectively, p \ 0.05 for all comparisons) (Table 7;
Fig. 1b). There was a statistically significant correlation
between TopBP1 mRNA and protein expressions (Spear-
man correlation coefficient for CC and CT genotype 0.76
and 0.82, respectively, p \ 0.05 for all comparisons).
However, not in all cases with positive mRNA expression
we could detected TopBP1 protein. Both mRNA and pro-
tein was detected in 306 of 506 CC samples, in 14 of 23 of
CT samples and 3 of 5 TT samples.
Discussion
The biological functions of TopBP1 protein as well as its
close relation with BRCA1 suggest a crucial role of this
protein in the maintenance of genome integrity and cell
cycle regulation. Published data on the involvement of
Table 1 Selected baseline characteristics of breast cancer cases and
controls with questionnaire data
Cases (n, %)
(n = 534)
Controls (n, %)
(n = 556)
pa
Age (years)
\45 123 (23.0) 189 (34.0)
45–54 133 (25.0) 139 (25.0)
55–64 150 (28.1) 122 (21.9)
[64 128 (23.9) 106 (19.1) \0.001
Family history of
breast cancerb
Yes 64 (11.9) 50 (9.0)
No 470 (88.1) 506 (91.0) 0.11
Obesity (BMI
C30 kg/m2)c
Yes 213 (39.9) 161 (28.9)
No 321 (60.1) 395 (71.1) \0.0001
Smoking statusd
Never smokers 96 (18.0) 155 (27.9)
Formet smokers 240 (44.9) 255 (45.9)
Current smokers 198 (37.1) 146 (26.2) \0.001
Alcohol intakee
Never/rare 43 27
Light 201 223
Moderate 163 171
Heavy 116 127
Ex-drinker 11 8 0.24
Menarche (years)
10 11 (2.1) 0 (0.0)
11 101 (18.9) 106 (19.2)
12 171 (32.1) 200 (35.9)
13 144 (26.9) 167 (30.0)
14 91 (17.1) 72 (12.9)
C15 16 (2.9) 11 (2.0) \0.01
Used oral
contraceptivesf
Yes 344 (64.4) 283 (50.1)
No 190 (35.6) 273 (49.9) \0.0001
Parity
Nulliparous 114 (21.3) 128 (23.0)
1 125 (23.4) 144 (25.9)
2 140 (26.2) 156 (28.0)
3 98 (18.3) 94 (16.9)
C4 57 (10.8) 34 (6.2) 0.07
Menopausal statusg
Premenopausal 192 (35.9) 228 (41.0)
Postmenopausal 342 (64.1) 328 (59.0) 0.09
Use of menopausal
hormonesf
Never 308 (57.7) 384 (69.1)
Estrogen 144 (27.0) 94 (16.9)
Table 1 continued
Cases (n, %)
(n = 534)
Controls (n, %)
(n = 556)
pa
Progestin 32 (6.0) 23 (4.1)
Combined 50 (9.3) 55 (9.9) \0.001
a v2 test
b Family history defined as self-reporting of at least one first-degree
relative with known breast cancer
c Body mass index (BMI) was calculated as current weight in kilo-
grams divided by height in meters squared
d Participants who reported smoking at least 100 cigarettes in their
lifetime and who, at the time of survey, smoked either every day or
some days were defined as current smoker. Participants who reported
smoking at least 100 cigarettes in their lifetime and who, at the time
of the survey, did not smoke at all were defined as former smoker.
Participants who reported never having smoked 100 cigarettes were
defined as never smoker
e Never/rare, \1 U/week; light, 1–8.9 U/week; moderate, 9–17.9 U/
week; heavy, C18 U/week; where 1 U = 22 g ethanol
f Regular drug use was defined as self-report use of oral contracep-
tives for 6 months or longer
g Menopause was defined as the time of the last menstrual period
(or menstrual flow of any amount). None of the women involved in
the study had undergone a hysterectomy
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TopBP1 in breast carcinogenesis are very limited. However,
the aberrant expression of TopBP1 protein in breast cancer
was shown. Immunohistochemical analysis of TopBP1 level
demonstrated that this protein was expressed almost exclu-
sively in nuclei of the normal breast epithelium while in
breast cancer samples TopBP1 was detected in nucleus and/
or in cytoplasm [14]. Analysis of TopBP1 protein expression
in feline and canine mammary neoplasms revealed that most
TopBP1 immunohistochemical staining was nuclear but
both nuclear and cytoplasmic staining was observed as the
degree of malignancy increased. Expression of TopBP1
protein was also correlated with histological grade of neo-
plasms [14, 15]. Patients with overexpression of TopBP1
tend to have higher grades of breast cancer and negative
estrogen receptor status compared with those without
overexpression of this protein and have significantly shorter
overall survival time [16]. The results of our earlier studies
concerning expression of TopBP1 in hereditary breast can-
cer showed lower TopBP1 mRNA expression in lobular
carcinoma compared with ductal carcinoma. The level of
TopBP1 mRNA appeared to be lower in poorly differenti-
ated (III grade) hereditary breast cancer in comparison
with moderately (II grade) and well-differentiated cancer
(I grade). However, the immunohistochemistry and Western
blot analyzes showed significantly increased of TopBP1
protein level in poorly differentiated breast cancer (III
grade). Our data suggested that increased level of TopBP1
protein might be associated with progression of hereditary
breast cancer [17].
Two SNPs (rs116195487 and rs185903567) of the five
listed in the NCBI’s SNP database were not observed in the
30UTR region of TopBP1 gene in our studied groups. This
allows to conclude that these polymorphisms do not occur
in the Polish population.
In this study, we demonstrated for the first time that
rs115160714 in the 30UTR region of TopBP1 gene is sig-
nificantly associated with breast cancer risk. Compared to
homozygous common allele carriers, heterozygous for the
T variant were found to be at a significant 3.54-fold
increased risk of developing breast cancer (95 % CI =
1.56–8.39; p = 0.002).
Since genetic alteration to the 30UTR sequence can
increase or decrease the half- life of the mRNA leading to
greater or lesser protein levels we presumed that
rs115160714 may affect TopBP1 expression. We found out
that mean TopBP1 mRNA and protein levels were higher
in case of individuals with CT or TT genotype.
There are several regulatory sequences in the 30UTR
that can affect expression, i.e. polyadenylation signal, AU-
rich elements and binding sites for miRNAs [18]. The
rs115160714 was not located in or close to any of these
sites except miRNAs binding sites. Thus we suggested that
polymorphism rs115160714 could change stability of
TopBP1 mRNA by affecting miRNA binding.
MicroRNAs are a class of regulatory RNAs reported to
modulate various biological processes and predicted to
regulate as many as 30 % of human mRNAs. The miRNA
targeting is determined by the nature and extent of the
complementarity between an miRNA and its target
sequence in the 30UTR of mRNA. Thus, a noncoding
polymorphism residing in the miRNA or the miRNA target
sequence may play a role in mRNA degradation or trans-
lational repression, which post-transcriptionally regulates
gene expression, with a concomitant alteration in pheno-
type [19, 20].
To identify miRNAs that likely target the vicinity of
the rs115160714 polymorphism in the TopBP1 30UTR,
we utilized a computational algorithm, MicoInspector
(http://mirna.imbb.forth.gr/microinspector/) that yielded
three candidate miRNAs, miR-3138, miR-4302 and miR-
1207-5p, whose seed sequences are complementary to
the TopBP1 mRNA sequence around the rs115160714
polymorphism.
We did not find any literature data about the miR-3138
and miR-4302 and there is only one study concerning miR-
1207-5p. Papagregoriou et al. [21] demonstrated that var-
iant 1936T of miRSNP (rs13385) in heparin binding epi-
dermal growth factor (HBEGF) prevents miR-1207-5p
from down-regulation of HBEGF in podocytes [22]. We
speculate that our findings may be explained on the basis of
a similar mechanism. Figure 2 shows a hypothetical dia-
gram of the interaction between fragment of TopBP1
Table 2 The clinicopathological characteristics of 534 patients with
breast cancer
Variable Mean ± SD or n (%)
Age (years) 54.76 ± 7.35
Histopathological grading
1 112 (21.0)
2 208 (38.9)
3 128 (24.0)
1 ? 2 86 (16.1)
Primary tumor stage
T1-2N0M0 389 (72.8)
T2-4N1M0 145 (27.2)
Tumor size
B2 cm 313 (58.6)
2–5 cm 219 (41.0)
[5 cm 2 (0.4)
ER and PR status
ER?PR? 341 (63.8)
ER?PR-/ER-PR? 112 (21.0)
ER-PR- 81 (15.2)
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30UTR sequence and miR-1207-5p. Nonetheless, further
experiments with other algorithms are needed to prove
above speculation.
We don’t know the exact biological consequences of
changes in TopBP1 expression level. However, increased
expression of TopBP1 can cause deregulation of p53
activity. TopBP1 interacts with p53 binding domain and
inhibits the promoter-binding activity of p53 [16]. Alter-
ation of balance between TopBP1 and p53 activity may
have impact on breast carcinogenesis.
TopBP1 is an essential protein that has numerous roles
in the maintenance of genomic integrity. In particular, it is
required for the activation of ATR and participates in DNA
damage response and DNA replication [9]. Taking into
Table 3 Frequency distribution
of the TopBP1 genotypes/alleles
in cases and controls, and the
risk of breast cancer
del allele deletion
a Adjusted for age, family
history, smoking status, alcohol
intake, BMI, menarche, parity,
menopausal status, and use of
contraceptive and menopausal
hormones
b Testing additive genetic
model (Cochran–Armitage test
for trend)
c Testing dominant genetic
model
d Testing recessive genetic
model
Variables Cases (n, %)/controls (n, %) OR (95 % CI)a p
rs116645643
AA 512 (95.9)/545 (98.0) 1.00 (ref.)
AG 21 (3.9)/11 (2.0) 2.19 (0.96–4.31) [0.05
GG 1 (0.2)/0 (0.0) –
A 1045 (97.8)/1101 (99.0) 1.00 (ref.)
G 23 (2.1)/11 (0.1) 2.22 (1.11–4.52) 0.03
p-trendb 0.05
AG or GG vs. AAc 2.16 (1.02–4.47) [0.05
AG or AA vs GGd – –
rs115160714
CC 506 (94.7)/548 (98.6) 1.00 (ref.)
CT 23 (4.4)/7 (1.2) 3.54 (1.56–8.39) 0.002
TT 5 (0.9)/1 (0.2) 5.40 (0.63–46.64) 0.004
C 1035 (96.9)/1103 (99.2) 1.00 (ref.)
T 33 (3.1)/9 (0.8) 3.97 (1.81–8.25) 0.001
p-trendb 0.0006
CT or TT vs. CCc 3.81 (1.63–8.34) 0.001
CT or CC vs. TTd 5.23 (0.65–45.07) 0.15
rs112843513
CC 391 (73.2)/389 (70.0) 1.00 (ref.)
C/delC 143 (26.8)/167 (30.0) 0.80 (0.67–1.06) 0.28
delC/delC 0 (0.0)/0 (0.0) –
C 925 (86.6)/945 (85.0) 1.00 (ref.)
delC 143 (13.4)/167 (15.0) 0.83 (0.62–1.14) 0.22
p-trendb 0.24
C/delC or delC/delC vs. CCc 0.86 (0.65–1.11) 0.23
C/delC or CC vs. delC/delCd – –
Table 4 The distribution of TopBP1 polymorphisms combined genotypes in breast cancer cases and controls
rs115160714
CC CT TT
rs116645643 AA and rs112843513 CC 371 (69.5)/379 (68.2) 1 (0.2)/1 (0.2) 0 (0.0)/1 (0.2)
rs116645643 AA and rs112843513 C/delC 117 (21.9)/160 (28.8) 19 (3.5)/4 (0.7) 4 (0.7)/0 (0.0)
rs116645643 AG and rs112843513 CC 17 (3.2)/7 (1.2) 1 (0.2)/1 (0.2) 0 (0.0)/0(0.0)
rs116645643 AG and rs112843513 C/delC 0 (0.0)/0 (0.0) 2 (0.4)/1 (0.2) 1 (0.2)/0 (0.0)
rs116645643 GG and rs112843513 CC 1 (0.2)/2 (0.3) 0 (0.0)/0 (0.0) 0 (0.0)/0 (0.0)
The table shows the number of cases and the percentage of genotype occurrence, respectively, in the study group and control population
Mol Biol Rep (2013) 40:3493–3502 3499
123
account the role of TopBP1 in DNA damage response we
were interested in exploring whether TopBP1 SNP–breast
cancer association varied according to smoking status or
alcohol consumption. Tobacco smoking is the best recog-
nized and most important risk factor of the development of
malignant cancer. Tobacco smoke contains several potent
chemical carcinogens and reactive oxygen species that may
produce bulky adducts, oxidative DNA damage, and DNA
strand breaks [23].
However, previous epidemiologic studies investigating
the association of cigarette smoking and breast cancer
showed inverse, null or positive associations. It has been
suggested that the genetic background might modify the
association between tobacco smoke and breast cancer. A
few studies have shown that defective DNA repair system
modestly increases tobacco-related breast cancer risk
[24–28].
We found out significant breast cancer prevalence in
group of smokers who were T allele carriers. Thus, poly-
morphisms in TopBP1 gene may modify the relationship
between breast cancer and smoking.
There is strong epidemiological evidence that con-
sumption of alcoholic beverages increases the risk of can-
cers of the oral cavity and pharynx, esophagus, and larynx.
Alcohol drinking has also been linked to breast cancer in
women [29]. Acetaldehyde, the primary metabolite of eth-
anol generates several types of DNA adducts that block
DNA replication and affect DNA damage response [30].
Our results did not show any association between alcohol
intake and increased risk of breast cancer in Polish popu-
lation. TopBP1 polymorphism did not changed alcohol
consumption-breast cancer risk relationship.
In conclusion, our results showed that rs115160714
polymorphism can increase breast cancer risk and is
associated with changes in TopBP1 expression.
Table 5 Adjusted odds ratio for relation between TopBP1 genotypes
and different tumor grades and stages
Variables Grade (n, %) OR (95 % CI)a p
Low grade High grade
(n = 406) (n = 128)
CC 397 (97.8) 109 (85.1) 1.00 (ref.)
CT 8 (2.0) 15 (11.7) 6.83 (2.75–16.86) 0.0001
TT 1 (0.2) 4 (3.2) 14.59 (1.56–134.81) 0.002
C 802 (98.8) 233 (91.0) 1.00 (ref.)
T 10 (1.22) 23 (9.0). 7.94 (3.66–17.18) 0.0001
Tumor stages (n, %)
T1-2N0M0 T2-4N1M0
(n = 389) (n = 145)
CC 382 (98.2) 124 (85.5) 1.00 (ref.)
CT 5 (1.3) 18 (12.4) 11.07 (3.92–31.52) 0.0001
TT 2 (0.5) 3 (2.1) 4.64 (0.77–28.23) 0.07
C 769 (98.8) 266 (91.7) 1.00 (ref.)
T 9 (1.2) 24 (8.3) 7.72 (3.46–17.03) 0.0001
a Adjusted for age, family history, smoking status, alcohol intake,
BMI, menarche, parity, menopausal status, and use of contraceptive
and menopausal hormones
Table 6 Comparison of the TopBP1 genotypes prevalence according to smoking status and adjusted odds ratio for relation between TopBP1
genotypes and smoking
Genotypes
Cases (n, %) Controls (n, %)
Smoking status CC CT TT CC CT TT pa
n = 506 n = 23 n = 5 n = 548 n = 7 n = 1
Smokersb 163 (30.5) 7 (1.3) 3 (0.6) 224 (40.3) 2 (0.3) 1 (0.2) 0.04
Non-smokersb 343 (64.2) 16 (3.0) 2 (0.4) 324 (58.3) 5 (0.9) 0 (0.0) 0.11
Genotypes in smokers Cases (n, %) Controls (n, %) OR (95 % CI)c p
CC 163 (94.2) 224 (98.7) 1.00 (ref.)
CT 7 (4.0) 2 (0.9) 4.82 (0.96–23.76) 0.03
TT 3 (1.8) 1 (0.4) 4.11 (0.45–40.37) 0.19
C 333 (96.2) 450 (99.1) 1.00 (ref.)
T 13 (3.8) 4 (0.9) 4.35 (1.43–13.66) 0.005
a v2 test
b Smoking was grouped into ‘‘smokers’’ and ‘‘non-smokers’’ based on self-reported usage or data obtained from family. Smoking factor was
considered positive when the subject smoked at least five cigarettes in a day for more than 1 year during the last 10 years
c Adjusted for age, family history, alcohol intake, BMI, menarche, parity, menopausal status, and use of contraceptive and menopausal hormones
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